ReviewGenes & diseases2026
Immune microenvironment in autosomal dominant polycystic kidney disease.
Review in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The effect of tolvaptan on total kidney volume and inflammatory markers in autosomal dominant polycystic kidney disease.Clinical and experimental nephrology · 2026Article
- Combination siRNA delivery as a therapeutic strategy for ADPKD.bioRxiv : the preprint server for biology · 2026Article
- A new conceptual framework for PKD1 in ADPKD; integrating DNA structures and inflammation.BMC nephrology · 2026Review
- Novel Compounds as Polycystin‑1 Correctors for Treating Autosomal Dominant Polycystic Kidney Disease.ACS medicinal chemistry letters · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a common hereditary renal disorder characterized by the progressive development of fluid-filled cysts within the kidneys, leading to renal dysfunction and potentially life-threatening complications. While ADPKD has long been considered a primarily genetic disorder, emerging evidence suggests that the immune microenvironment within the kidney plays a pivotal role in disease progression and severity. This review explored the intricate interplay between immune cells, inflammatory microenvironment, inflammatory pathways, complement system, and ADPKD, shedding light on the various immune components and mechanisms contributing to ADPKD pathogenesis. Key findings suggest that renal immune cell infiltration, inflammation, and the complement system could take part in cyst growth, renal fibrosis, and ADPKD progression. Inflammation, in particular, stands out as a prime candidate for therapeutic intervention. Moreover, recent studies have unveiled the involvement of immune checkpoints, such as PD-1 and its ligand PD-L1, in modulating the immune response within ADPKD kidneys. In conclusion, this review highlights the emerging paradigm shift in the understanding of ADPKD, emphasizing the pivotal role of the immune microenvironment in disease pathogenesis. Targeted therapies aimed at modulating immune responses and addressing immune-related checkpoints may hold promise for the development of novel treatments to improve the clinical outcomes of ADPKD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.